Mouse 11β-hydroxysteroid dehydrogenase type 2 for human application: Homology modeling, structural analysis and ligand-receptor interaction

Cancer Informatics

Volumn 10, Issue , 2011, Pages 287-295

  Yamaguchi, Hideaki ^a   Akitaya, Tatsuo ^a   Kidachi, Yumi ^b   Kamiie, Katsuyoshi ^b   Noshita, Toshiro ^c   Umetsu, Hironori ^d   Ryoyama, Kazuo ^b  

^a MEIJO UNIVERSITY   (Japan)

^b AOMORI UNIVERSITY   (Japan)

^c PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^d GIFU SHOTOKU GAKUEN UNIVERSITY   (Japan)

Author keywords

11 HSD2; Anticancer drug; Homology modeling; Molecular operating environment (MOE); Tumor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2;

ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; STATIC ELECTRICITY; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS;

EID: 83455210492     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S8725     Document Type: Article

References (36)

1. Oppermann UC, Filling C, Berndt KD, et al. Active site directed mutagenesis of 3 beta/17 beta-hydroxysteroid dehydrogenase establishes differential effects on short-chain dehydrogenase/reductase reactions. Biochemistry. 1997;36:34-40.
2. Filling C, Berndt KD, Benach J, et al. Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem. 2002;277:25677-84.
3. Zhang M, Xu J, Yao B, et al. Inhibition of 11â-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest. 2009;119:876-85.
4. Nigawara T, Iwasaki Y, Asai M, et al. Inhibition of 11â-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells. Endocrinology. 2006;147:769-72.
5. Koyama K, Myles K, Smith R, Krozowski Z. Expression of the 11â- hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells. J Steroid Biochem Mol Biol. 2001;76:153-9.
6. Cohen PG. Estradiol induced inhibition of 11â-hydroxysteroid dehydrogenase 1: an explanation for the postmenopausal hormone replacement therapy effects. Med Hypotheses. 2005;64:989-91.
7. Zbankova S, Bryndova J, Kment M, Pacha J. Expression of 11â- hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer. Cancer Lett. 2004;210:95-100.
8. Yamaguchi H, Noshita T, Yu T, et al. Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. Eur J Med Chem. 2010;45: 2943-8.
9. Yamaguchi H, Kidachi Y, Kamiie K, Noshita T, Umetsu H, Ryoyama K. Glycyrrhetinic acid induces anoikis-like death and cytoskeletal disruption in the central nervous system tumorigenic cells. Biol Pharm Bull. 2010;33: 321-24.
10. Rabbitt EH, Lavery GG, Walker EA, et al. Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB J. 2002;16:36-44.
11. Stewart PM, Prescott SM. Can licorice lick colon cancer? J Clin Invest. 2009;119:760-3.
12. Rabbitt EH, Ayuk J, Boelaert K, et al. Abnormal expression of 11beta-HSD type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation Oncogene. 2003:22;1663-7.
13. Kurogi Y, Guner OF. Pharmacophore modeling and threedimensional database searching for drug design using catalyst. Curr Med Chem. 2001;8:1035-55.
14. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discovery Today. 2004;9:276-85.
15. Jorgensen WL. The many roles of computation in drug discovery. Science. 2004;303:1813-8.
16. Carvajal CA, Gonzalez AA, Romero DG, et al. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 2003;88:2501-7.
17. Koch MA, Wittenberg LO, Basu S, et al. Compound library development guided by protein structure similarity clustering and natural product structure. Proc Natl Acad Sci U S A. 2004;101:16721-6.
18. Yamaguchi H, Akitaya T, Yu T, et al. Homology modeling and structural analysis of 11â-hydroxysteroid dehydrogenase type 2. Eur J Med Chem. 2011;46:1325-30.
19. Huang Y, Li X, Lin H, et al. Regulation of 11beta-hydroxysteroid dehydrogenase 1 and 2 by IGF-1 in mice. Biochem Biophys Res Commun. 2010;391: 1752-6.
20. Wan ZK, Chenail E, Xiang J, et al. Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J Med Chem. 2009;52:5449-61.
21. Levitt M. Accurate modeling of protein conformation by automatic segment matching. J Mol Biol. 1992;226:507-33.
22. Fechteler T, Dengler U, Schomberg D. Prediction of protein three- dimensional structures in insertion and deletion regions: a procedure for searching data bases of representative protein fragments using geometric scoring criteria. J Mol Biol. 1995;253:114-31.
23. Bowie JU, Lüthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science. 1991;253:164-70.
24. Lüthy R, Bowie JU, Eisenberg D. Assessment of protein models with threedimensional profiles. Nature. 1992;356:83-5.
25. Zhang C, Vasmatizis G, Cornette JL, DeLisi C. Determination of atomic desolvation energies from the structures of crystallized proteins. J Mol Biol. 1997;267:707-26.
26. Liang J, Edelsbrunner H, Fu P, Sudhakar PV, Subramaniam S. Analytical shape computation of macromolecules: I. molecular area and volume through alpha shape. Proteins. 1998;33:1-17.
27. Liang J, Edelsbrunner H, Fu P, Sudhakar PV, Subramaniam S. Analytical shape computation of macromolecules: II. Inaccessible cavities in proteins. Proteins. 1998;33:18-29.
28. Goto J, Kataoka R, Hirayama N. Ph4Dock: pharmacophore-based proteinligand docking. J Med Chem. 2004;47:6804-11.
29. Goto J, Kataoka R, Muta H, Hirayama N. ASEDock-Docking based on alpha spheres and excluded volumes. J Chem Inf Model. 2008;48:583-90.
30. Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996;17:490-519.
31. Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev. 2007;39:87-144.
32. Obeid J, White PC. Tyr-179 and Lys-183 are essential for enzymatic activity of 11 beta-hydroxysteroid dehydrogenase. Biochem Biophys Res Commun. 1992;188:222-7.
33. Miguet L, Zhang Z, Barbier M, Grigorov MG. Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors. J Comput Aided Mol Des. 2006;20:67-81.
34. Lovell SC, Davis IW, Arendall III WB, et al. Structure validation by Cα geometry: φ{symbol}, ψ and Cβ deviation. Proteins. 2003;50:437-50.
35. Awale M, Kumar V, Saravanan P, Mohan CG. Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors. J Mol Model. 2010;16:475-88.
36. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem. 2008;29:1693-8.